Saligren 42 capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)

What are Saligren capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)?

Saligren capsules contain 30 mg of cevimeline hydrochloride hydrate, a potent parasympathomimetic and muscarinic agonist. This active compound exerts its therapeutic effects by specifically targeting the M1 and M3 receptors of the parasympathetic nervous system, which are abundantly present in the salivary glands and smooth muscle cells. By binding to these receptors, the drug triggers a cascade of intracellular events, leading to increased secretion of acetylcholine, a neurotransmitter responsible for various parasympathetic functions, including salivation.

The mechanism of action of cevimeline hydrochloride is pivotal in treating conditions characterized by oral dryness, such as Sjogren's syndrome. This autoimmune disorder affects the exocrine glands, leading to reduced salivary flow and oral discomfort. Saligren capsules, through their activation of M1 and M3 receptors, stimulate the secretion of the salivary glands, thereby promoting the production of saliva. This increase in saliva production helps alleviate the dryness in the oral cavity and provides symptomatic relief to patients suffering from Sjogren's syndrome.

Clinical studies have substantiated the effectiveness of Saligren capsules in managing oral dryness caused by Sjogren's syndrome. Over a span of 52 weeks, patients who received the 30 mg cevimeline hydrochloride capsules demonstrated a significant improvement in salivary flow rates, which directly correlated with reduced oral dryness. Furthermore, these studies revealed that patients experienced substantial relief from subjective symptoms such as dry mouth, difficulty in swallowing, and a parched feeling.

Additionally, cevimeline hydrochloride has shown promising results in treating dry mouth associated with psychosomatic oral disease. The drug's ability to enhance salivary secretion makes it an effective therapeutic option for patients dealing with oral dryness related to psychological factors.

Active principles: cevimeline hydrochloride hydrate

Amount: 42 capsules

Maker: Nippon Kayaku Co., Ltd., Tokyo, Japan

Indications: treatment of dry mouth in the patients with Sjogren's syndrome

How to take

Adults should take 1 capsule (30 mg of the active principle) 3 times a day after meals.

Contraindications: do not use for the following patients:

• pregnant and breastfeeding women,
• patients with ischemic heart disease (myocardial infarction, angina pectoris etc.),
• patients with bronchial asthma or chronic obstructive pulmonary disease,
• patients with gastrointestinal obstruction or urinary bladder neck obstruction,
• patients with epilepsy,
• patients with Parkinsonian syndrome or Parkinson's disease,
• patients with iritis.

Important information

As this medicine may cause miosis, patients should take care when driving a car during the evening, or operating dangerous machinery in a dark place.

If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.